Year: 2026
Type: article
Abstract: Nonalcoholic fatty liver disease (NAFLD) has become a major public health concern. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors. PPARs are categorized into three subtypes: PPARα, β/δ, and γ. Three subtypes of PPARs play crucial roles in lipid and glucose metabolism, inflammation and fibrosis. This review summarizes randomized controlled trials on the use of PPAR agonists in the treatment of NAFLD. PPARα and PPARβ/δ agonists control circulatory lipids well, but they do not yield enough liver benefits. PPARγ agonists, particularly pioglitazone, are recommended for NAFLD treatment. PPARα/γ agonists and PPARα/β/γ agonists are plausible in the treatment of NAFLD. More clinical studies are still in need to properly unveil the efficacy of PPAR agonists in the treatment of NAFLD.
Source: Frontiers in Pharmacology
Authors: Xiaoling Li, Junjie Zhang, Bo Wei, Huan Tong
Institutions: Sichuan University, West China Hospital of Sichuan University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G2468642306
OpenAlex ID: W7141594622